Search - tctmd.com

Displaying 21 - 31 of 31

Sort: Relevancy | Date

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Industry News

Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy

August 31, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

Shelley Wood

July 20, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Industry News

Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA

January 26, 2016

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

News Industry News

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

May 28, 2015

News Daily News

Pulmonary Denervation Shows Promise for Resistant Pulmonary Hypertension

Yael L. Maxwell

July 19, 2013

News Industry News

Cardiome Announces Commercialization Partnership For BRINAVESS™ In Select European Markets

July 03, 2013

News Industry News

Heart Metabolics Receives Funding for U.S. Clinical Development of Heart Failure Drug

January 02, 2013

Advertisement

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Pulmonary Denervation Shows Promise for Resistant Pulmonary Hypertension

Cardiome Announces Commercialization Partnership For BRINAVESS™ In Select European Markets

Heart Metabolics Receives Funding for U.S. Clinical Development of Heart Failure Drug

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content